InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Journey Medical Corp

DERM Clue Score30
United States Fiscal year ends December CIK 0001867066
$6.31 +6.05% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $6.31 +120.63% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Nov 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Revenue44.5Operating income7.9Net income5.3EPS, diluted0.49Fiscal year 2021Revenue63.1 +41.8%Operating income−34.9Net income−44.0 −932.7%EPS, diluted−4.32Fiscal year 2022Revenue71.0 +12.5%Operating income−27.5Net income−29.6EPS, diluted−1.69Fiscal year 2023Revenue59.7 −16.0%Operating income−2.1Net income−3.9EPS, diluted−0.21Fiscal year 2024Revenue55.1 −7.6%Operating income−13.7Net income−14.7EPS, diluted−0.72Fiscal year 2025Revenue61.2 +11.1%Operating income−8.2Net income−11.4EPS, diluted−0.47
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 44.5 63.1 71.0 59.7 55.1 61.2
Growth +41.8% +12.5% −16.0% −7.6% +11.1%
Operating income 7.9 −34.9 −27.5 −2.1 −13.7 −8.2
Net income 5.3 −44.0 −29.6 −3.9 −14.7 −11.4
Growth −932.7%
EPS, diluted 0.49 −4.32 −1.69 −0.21 −0.72 −0.47

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Operating margin17.6%Net margin11.9%Fiscal year 2021Operating margin−55.2%Net margin−69.7%Fiscal year 2022Operating margin−38.8%Net margin−41.7%Free cash flow margin−47.2%Fiscal year 2023Operating margin−3.5%Net margin−6.5%Free cash flow margin0.4%Fiscal year 2024Operating margin−24.8%Net margin−26.6%Free cash flow margin−43.8%Fiscal year 2025Operating margin−13.3%Net margin−18.7%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin 17.6% −55.2% −38.8% −3.5% −24.8% −13.3%
Net margin 11.9% −69.7% −41.7% −6.5% −26.6% −18.7%
Free cash flow margin n/a n/a −47.2% 0.4% −43.8% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow5.1Fiscal year 2021Operating cash flow−2.2Fiscal year 2022Operating cash flow−13.5Capital expenditure−20.0Free cash flow−33.5Fiscal year 2023Operating cash flow5.2Capital expenditure−5.0Free cash flow0.2Fiscal year 2024Operating cash flow−9.1Capital expenditure−15.0Free cash flow−24.1 −10,152.9%Fiscal year 2025Operating cash flow−12.4
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow 5.1 −2.2 −13.5 5.2 −9.1 −12.4
Capital expenditure n/a n/a −20.0 −5.0 −15.0 n/a
Free cash flow n/a n/a −33.5 0.2 −24.1 n/a
Growth −10,152.9%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2020Cash8.2Shareholders’ equity10.3Fiscal year 2021Cash49.1Shareholders’ equity42.0Fiscal year 2022Cash32.0Total debt19.8Net cash (debt)12.2Shareholders’ equity17.0Debt to equity1.17Fiscal year 2023Cash27.4Total debt14.6Net cash (debt)12.8Shareholders’ equity20.4Debt to equity0.72Fiscal year 2024Cash20.3Total debt24.9Net cash (debt)−4.6Shareholders’ equity20.1Debt to equity1.24Fiscal year 2025Cash24.1Total debt25.3Net cash (debt)−1.2Shareholders’ equity31.9Debt to equity0.79
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 8.2 49.1 32.0 27.4 20.3 24.1
Total debt n/a n/a 19.8 14.6 24.9 25.3
Net cash (debt) n/a n/a 12.2 12.8 −4.6 −1.2
Shareholders’ equity 10.3 42.0 17.0 20.4 20.1 31.9
Debt to equity n/a n/a 1.17 0.72 1.24 0.79

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
44.5 63.1 71.0 59.7 55.1 61.2
Growth +41.8% +12.5% −16.0% −7.6% +11.1%
14.6 32.1 30.8 22.9 20.9 20.9
n/a 2.7 10.9 7.5 9.9 0.5
22.1 39.8 59.5 43.9 40.2 44.4
7.9 −34.9 −27.5 −2.1 −13.7 −8.2
Growth −544.3%
7.2 −42.4 −29.6 −3.6 −14.6 −11.4
1.9 1.6 0.1 0.2 0.1 0.1
5.3 −44.0 −29.6 −3.9 −14.7 −11.4
Growth −932.7%
Per share
0.58 −4.32 −1.69 −0.21 −0.72 −0.47
0.49 −4.32 −1.69 −0.21 −0.72 −0.47
Growth −981.6%
9.1 10.2 17.5 18.2 20.4 24.5
10.8 10.2 17.5 18.2 20.4 24.5
Growth −6.0% +72.0% +4.0% +12.1% +19.9%

† The diluted share count jumps at 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 6.6% a year over five years.
  • Operating margin is down 31.0 points on five years ago, at -13.3%.
  • A net loss in 5 of 6 years on file.